A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Eribulin Mesylate|DRUG: Pembrolizumab
Sponsor: Dana-Farber Cancer Institute
Collaborators: Merck Sharp & Dohme LLC